Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Corbus Pharmaceuticals initiated with a Buy at Roth Capital » 08:02
07/07/20
07/07
08:02
07/07/20
08:02
CRBP

Corbus Pharmaceuticals

$7.90 /

-0.05 (-0.63%)

Roth Capital analyst…

Roth Capital analyst Elemer Piros initiated coverage of Corbus Pharmaceuticals with a Buy rating and $40 price target. The analyst believes that the upcoming pivotal trial readouts could place Corbus into the billion-dollar-plus biotech club. Piros notes that the company is conducting potentially pivotal clinical trials in patients with systemic sclerosis, cystic fibrosis and dermatomyositis, with two out of the three studies reading out in Q3/Q4 of 2020.

ShowHide Related Items >><<
CRBP Corbus Pharmaceuticals
$7.90 /

-0.05 (-0.63%)

CRBP Corbus Pharmaceuticals
$7.90 /

-0.05 (-0.63%)

06/22/20 BTIG
Corbus Pharmaceuticals' Phase 2b CF data readouts seen in Q3, says BTIG
06/16/20 BTIG
Corbus Pharmaceuticals initiated with a Buy at BTIG
06/03/20 Nomura Instinet
Corbus Pharmaceuticals price target raised to $32 from $12 at Nomura Instinet
03/26/20
Fly Intel: Top five analyst initiations
CRBP Corbus Pharmaceuticals
$7.90 /

-0.05 (-0.63%)

  • 07
    Feb
Over a week ago
Hot Stocks
Corbus Pharmaceuticals presents data on ACR CRISS Score » 08:25
06/29/20
06/29
08:25
06/29/20
08:25
CRBP

Corbus Pharmaceuticals

$7.81 /

-0.02 (-0.26%)

Corbus Pharmaceuticals…

Corbus Pharmaceuticals Holdings announced the presentation of 3 abstracts at the 6th Systemic Sclerosis World E-Congress. The data presented in these abstracts show that the American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis score positively correlates with improvements in multiple patient-reported outcomes. Importantly, the ACR CRISS score also correlates more strongly with these patient-reported outcomes than change in modified Rodnan Skin Score. Together, these data show that the ACR CRISS score broadly reflects changes from baseline in how patients feel and function. These data will be presented in a recorded oral presentation and two e-posters at the 6th Systemic Sclerosis World E-Congress on June 29, 2020. Two live discussions sessions for the oral presentation will be held during the Live Congress on July 12, 2020 at 16:00-16:30 UCT+2 time and on July 13, 2020 at 11:30-12:00 UCT+2 time. All three abstracts will be published in the Journal of Scleroderma and Related Disorders. In addition, the Company announced it will sponsor a satellite symposium titled "The Role of the Endocannabinoid System in Chronic Inflammation and Fibrosis" hosted by Professor Christopher Denton, MB, BS, PhD, FRCP, Head of Centre and Consultant Rheumatologist, University College London Division of Medicine, and Tracy Frech, M.D., MS, Director of the Systemic Sclerosis Clinic at the University of Utah Hospital and the Director of Clinical Trials for the Division of Rheumatology. The symposium will be held at the Live Congress on Sunday, July 12, 2020 at 14:30 UCT+2 time. Once the presentation is made public, it will be available along with the three abstracts on the Company's website in the Scientific Conferences section.

ShowHide Related Items >><<
CRBP Corbus Pharmaceuticals
$7.81 /

-0.02 (-0.26%)

CRBP Corbus Pharmaceuticals
$7.81 /

-0.02 (-0.26%)

06/22/20 BTIG
Corbus Pharmaceuticals' Phase 2b CF data readouts seen in Q3, says BTIG
06/16/20 BTIG
Corbus Pharmaceuticals initiated with a Buy at BTIG
06/03/20 Nomura Instinet
Corbus Pharmaceuticals price target raised to $32 from $12 at Nomura Instinet
03/26/20
Fly Intel: Top five analyst initiations
CRBP Corbus Pharmaceuticals
$7.81 /

-0.02 (-0.26%)

  • 07
    Feb
Recommendations
Corbus Pharmaceuticals' Phase 2b CF data readouts seen in Q3, says BTIG » 13:29
06/22/20
06/22
13:29
06/22/20
13:29
CRBP

Corbus Pharmaceuticals

$7.86 /

+ (+0.00%)

BTIG analyst Dae Gon Ha…

BTIG analyst Dae Gon Ha reiterated a Buy rating on Corbus Pharmaceuticals shares after the company announced completion of its last patient visit in the Phase 2b cystic fibrosis study and confirmed the topline results timing in Q3, which will occur after Phase 3 RESOLVE-1. The analyst continues to view the CF program as an intriguing call option for investors as it is externally funded by the Cystic Fibrosis Foundation and, if effective, likely address all CF patients. irrespective their underlying genotype or current treatment regimen.

ShowHide Related Items >><<
CRBP Corbus Pharmaceuticals
$7.86 /

+ (+0.00%)

CRBP Corbus Pharmaceuticals
$7.86 /

+ (+0.00%)

06/16/20 BTIG
Corbus Pharmaceuticals initiated with a Buy at BTIG
06/03/20 Nomura Instinet
Corbus Pharmaceuticals price target raised to $32 from $12 at Nomura Instinet
03/26/20
Fly Intel: Top five analyst initiations
03/26/20 Nomura Instinet
Corbus Pharmaceuticals initiated with a Buy at Nomura Instinet
CRBP Corbus Pharmaceuticals
$7.86 /

+ (+0.00%)

Hot Stocks
Corbus Pharmaceuticals reports last subject visit in Phase 2b study of lenabasum » 08:39
06/22/20
06/22
08:39
06/22/20
08:39
CRBP

Corbus Pharmaceuticals

$7.86 /

-0.09 (-1.13%)

Corbus Pharmaceuticals…

Corbus Pharmaceuticals Holdings announced that the last subject completed their final visit in the Company's Phase 2b JBT101-CF-002 trial of lenabasum for the treatment of cystic fibrosis. Topline results from the study are on track to readout in the third quarter of 2020, following the topline data from the RESOLVE-1 Phase 3 systemic sclerosis study. The Phase 2b trial is a multinational, 426-subject study evaluating the efficacy and safety of lenabasum in cystic fibrosis. This is a double-blind, randomized, placebo-controlled study, with dosing of lenabasum at 5 mg twice per day, lenabasum 20 mg twice per day or placebo twice per day for 28 weeks, with 4 weeks safety follow-up off active treatment. The primary efficacy endpoint is the event rate of pulmonary exacerbation. Secondary efficacy outcomes include other measures of PEx, change in forced expiratory volume in 1 second, % predicted, and change in Cystic Fibrosis Questionnaire-Revised respiratory domain score. The Phase 2b CF study is funded in part by a Development Award for up to $25 Million from the Cystic Fibrosis Foundation. Lenabasum has been granted Orphan Drug designation and Fast Track designation for the treatment of cystic fibrosis by the U.S. Food and Drug Administration and Orphan Designation for the treatment of cystic fibrosis from the European Medicines Agency.

ShowHide Related Items >><<
CRBP Corbus Pharmaceuticals
$7.86 /

-0.09 (-1.13%)

CRBP Corbus Pharmaceuticals
$7.86 /

-0.09 (-1.13%)

06/16/20 BTIG
Corbus Pharmaceuticals initiated with a Buy at BTIG
06/03/20 Nomura Instinet
Corbus Pharmaceuticals price target raised to $32 from $12 at Nomura Instinet
03/26/20
Fly Intel: Top five analyst initiations
03/26/20 Nomura Instinet
Corbus Pharmaceuticals initiated with a Buy at Nomura Instinet
CRBP Corbus Pharmaceuticals
$7.86 /

-0.09 (-1.13%)

Initiation
Corbus Pharmaceuticals initiated with a Buy at BTIG » 20:02
06/16/20
06/16
20:02
06/16/20
20:02
CRBP

Corbus Pharmaceuticals

$7.55 /

+0.425 (+5.97%)

BTIG analyst Dae Gon Ha…

BTIG analyst Dae Gon Ha initiated coverage of Corbus Pharmaceuticals with a Buy rating and $22 price target. The company is an "under-the-radar name developing lead candidate lenabasum for the treatment of rare but devastating rheumatic diseaseslike systemic sclerosis and dermatomyositis", the analyst tells investors in a research note. Dae Gon Ha adds that Corbus trades with a "modest" market cap while offering two phase 3 programs in addition to its externally funded programs in cystic fibrosis and systemic lupus erythematosus.

ShowHide Related Items >><<
CRBP Corbus Pharmaceuticals
$7.55 /

+0.425 (+5.97%)

CRBP Corbus Pharmaceuticals
$7.55 /

+0.425 (+5.97%)

06/03/20 Nomura Instinet
Corbus Pharmaceuticals price target raised to $32 from $12 at Nomura Instinet
03/26/20
Fly Intel: Top five analyst initiations
03/26/20 Nomura Instinet
Corbus Pharmaceuticals initiated with a Buy at Nomura Instinet
CRBP Corbus Pharmaceuticals
$7.55 /

+0.425 (+5.97%)

Over a month ago
Recommendations
Corbus Pharmaceuticals price target raised to $32 from $12 at Nomura Instinet » 12:41
06/03/20
06/03
12:41
06/03/20
12:41
CRBP

Corbus Pharmaceuticals

$7.00 /

-0.065 (-0.92%)

Nomura Instinet analyst…

Nomura Instinet analyst Christopher Marai raised the firm's price target on Corbus Pharmaceuticals to $32 from $12 and keeps a Buy rating on the shares ahead of of imminent lenabasum Phase 3 data in systemic sclerosis, Phase 2b data in cystic fibrosis, Phase 2a in systemic lupus erythematosus, and derisking safety data for CRB-4001, a CB1 inverse agonist. Marai believes the preclinical data presented at EULAR, together with CB2 expression in the skin, supports the striking clinical Ph2 results for lenabasum in SSc, further derisking the Phase 3 readout expected this summer and views Corbus's setup into the imminent data as "very attractive."

ShowHide Related Items >><<
CRBP Corbus Pharmaceuticals
$7.00 /

-0.065 (-0.92%)

CRBP Corbus Pharmaceuticals
$7.00 /

-0.065 (-0.92%)

03/26/20
Fly Intel: Top five analyst initiations
03/26/20 Nomura Instinet
Corbus Pharmaceuticals initiated with a Buy at Nomura Instinet
CRBP Corbus Pharmaceuticals
$7.00 /

-0.065 (-0.92%)

Hot Stocks
Corbus Pharmaceuticals publishes Phase 1b CF study patient demographics » 08:22
06/01/20
06/01
08:22
06/01/20
08:22
CRBP

Corbus Pharmaceuticals

$7.49 /

+0.04 (+0.54%)

Corbus Pharmaceuticals…

Corbus Pharmaceuticals Holdings announced baseline patient demographics and disease characteristics in its Phase 2b study of lenabasum in cystic fibrosis. The information was published in an electronic supplement of the Journal of Cystic Fibrosis in connection with the 43rd European Cystic Fibrosis Conference. Topline results from the Phase 2b cystic fibrosis study are on track for the summer of 2020.

ShowHide Related Items >><<
CRBP Corbus Pharmaceuticals
$7.49 /

+0.04 (+0.54%)

CRBP Corbus Pharmaceuticals
$7.49 /

+0.04 (+0.54%)

03/26/20
Fly Intel: Top five analyst initiations
03/26/20 Nomura Instinet
Corbus Pharmaceuticals initiated with a Buy at Nomura Instinet
CRBP Corbus Pharmaceuticals
$7.49 /

+0.04 (+0.54%)

Hot Stocks
Corbus reports last subject visit in RESOLVE-1 Phase 3 study of lenabasum » 08:35
05/27/20
05/27
08:35
05/27/20
08:35
CRBP

Corbus Pharmaceuticals

$8.00 /

-0.03 (-0.37%)

Corbus Pharmaceuticals…

Corbus Pharmaceuticals Holdings announced that the last subject completed their final visit in the Company's RESOLVE-1 Phase 3 trial of lenabasum for the treatment of systemic sclerosis. Topline results from the study are on track for summer 2020. The RESOLVE-1 Phase 3 trial is a multinational study evaluating the efficacy and safety of lenabasum in systemic sclerosis. This was a double-blind, randomized, placebo-controlled study, with dosing of lenabasum at 20 mg twice per day, or lenabasum at 5 mg twice per day, or placebo twice per day for 52 weeks, with a 28-day safety follow-up. Study subjects may then elect to participate in the ongoing open-label extension of RESOLVE-1. The primary efficacy endpoint is a composite score known as the ACR CRISS, measured at Week 52. ACR-CRISS was also the primary endpoint in the preceding Phase 2 study recently published in Arthritis & Rheumatology. Secondary efficacy endpoints include change from baseline at Week 52 in modified Rodnan skin score, Health Assessment Questionnaire- Disability index, and forced vital capacity percent predicted. Three hundred and sixty-five patients were enrolled in the study. Baseline disease characteristics of subjects in RESOLVE-1 are similar to those in the Phase 2 study and were recently presented at American College of Rheumatology 2019 Annual Meeting and European League Against Rheumatism 2020 E-Congress. Lenabasum has been granted Orphan Drug designation and Fast Track designation for the treatment of systemic sclerosis from the U.S. Food and Drug Administration and Orphan Designation for the treatment of systemic sclerosis from the European Medicines Agency.

ShowHide Related Items >><<
CRBP Corbus Pharmaceuticals
$8.00 /

-0.03 (-0.37%)

CRBP Corbus Pharmaceuticals
$8.00 /

-0.03 (-0.37%)

03/26/20
Fly Intel: Top five analyst initiations
03/26/20 Nomura Instinet
Corbus Pharmaceuticals initiated with a Buy at Nomura Instinet
CRBP Corbus Pharmaceuticals
$8.00 /

-0.03 (-0.37%)

Hot Stocks
Corbus Pharmaceuticals announces clinical program updates » 07:32
05/11/20
05/11
07:32
05/11/20
07:32
CRBP

Corbus Pharmaceuticals

$6.58 /

-0.08 (-1.20%)

Lenabasum: a novel, oral,…

Lenabasum: a novel, oral, selective cannabinoid receptor type 2 agonist: Topline results for lenabasum systemic sclerosis study remain on schedule for summer 2020, followed by cystic fibrosis study results. Systemic Sclerosis - Phase 3 "RESOLVE-1" topline results in SSc, a rare disease and the most lethal of the systemic autoimmune diseases, remain on track for the summer of 2020. The multicenter study of 365 patients is randomized 1:1:1 for twice a day dosing of lenabasum at 5 mg, 20 mg, or placebo for 52 weeks, with a 4-week follow up. The primary endpoint is ACR CRISS score. The open-label extension of this study is active. Cystic fibrosis - Phase 2b topline results of lenabasum in people with CF who are at high-risk for recurrent pulmonary exacerbation expected following RESOLVE-1 data results. The multicenter study of 426 patients is randomized 1:2:2 for twice a day dosing of lenabasum at 5 mg, 20 mg, or placebo for 28 weeks, with a 4-week follow up. The primary endpoint is event rate of pulmonary exacerbation. Dermatomyositis - Phase 3 "DETERMINE" study in DM, a rare and life-threatening autoimmune disease characterized by skin and muscle inflammation, is ongoing with enrollment expected to be completed in 2020, and topline data expected in 2021. The double-blind, randomized, placebo controlled, multinational study expects to enroll 150 subjects. The primary endpoint is ACR / EULAR 2016 Total Improvement Score in Adult Dermatomyositis & Polymyositis. The open-label extension of this study is already active. Systemic Lupus Erythematosus - The randomized, double-blind, placebo-controlled, U.S. study, funded and managed by the National Institutes of Health, has enrolled 86/100 patients to date. CRB-4001: a peripherally restricted CB1 inverse agonist potentially for NASH: Phase 1 study of CRB-4001 continues to be expected to commence in the third quarter of 2020. The study will evaluate the safety, tolerability and pharmacokinetics of CRB-4001. CRB-4001 has demonstrated potent effects on glucose tolerance, insulin sensitivity, lipid metabolism, body fat, and hepatic fat in animal models of disease, with robust literature supporting these beneficial metabolic effects. Additional Candidate Compounds: Corbus anticipates the selection of an additional candidate compound this year for IND enabling pre-clinical studies.

ShowHide Related Items >><<
CRBP Corbus Pharmaceuticals
$6.58 /

-0.08 (-1.20%)

03/26/20
Fly Intel: Top five analyst initiations
03/26/20 Nomura Instinet
Corbus Pharmaceuticals initiated with a Buy at Nomura Instinet
Hot Stocks
Corbus Pharmaceuticals expects cash to fund operations into 4Q20 » 07:31
05/11/20
05/11
07:31
05/11/20
07:31
CRBP

Corbus Pharmaceuticals

$6.58 /

-0.08 (-1.20%)

The Company completed a…

The Company completed a public offering in February 2020 that raised approximately $43 million in net proceeds. The Company ended the quarter with approximately $46.6 million in cash and cash equivalents and expects its cash and cash equivalents on hand at March 31, 2020 together with the $7.5 million remainder of the expected milestone payments from the $25 million Development Award from the Cystic Fibrosis Foundation to fund operations into the fourth quarter of 2020.

ShowHide Related Items >><<
CRBP Corbus Pharmaceuticals
$6.58 /

-0.08 (-1.20%)

03/26/20
Fly Intel: Top five analyst initiations
03/26/20 Nomura Instinet
Corbus Pharmaceuticals initiated with a Buy at Nomura Instinet

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.